News & Commentary

09.08.21 | Firms News

Dr. Craig Gordon Launches Alternative Investment Firm GordonMD Global Investments

Today Craig Gordon, MD, a licensed physician with over a decade of buy-side experience managing global biopharmaceutical portfolios, proudly announces the launch of GordonMD Global Investments.

09.08.21

Dr. Craig Gordon Launches Alternative Investment Firm GordonMD Global Investments

Today Craig Gordon, MD, a licensed physician with over a decade of buy-side experience managing global biopharmaceutical portfolios, proudly announces the launch of GordonMD Global Investments.

09.12.22

Spotlight Therapeutics Appoints Nallakkan Arvindan, Ph.D., MBA, as EVP and Chief Technology Officer

Dr. Arvindan Brings Two Decades of Broad Industry Expertise in Technology Development and Operations

07.12.22

Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. as First Independent Board Member

Dr. Yver Brings More Than 30 Years of Industry Experience Including 11 Different Biologics and Small Molecule New Drug Approvals

03.22.22

Spotlight Therapeutics Raises $36.5 Million Series B to Advance a Pipeline of Cell-Targeted In Vivo CRISPR Gene Editing Biologics

Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced a $36.5M Series B financing to fuel a drive toward the clinic.

01.05.22

SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene CodingTM – A New Category of Genetic Medicine

SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.

11.03.21

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

We are excited to announce the completion of our Series B-1 financing, a $75 million raise co-led by GordonMD Global Investments and the EPIQ Capital Group.

09.07.22

The End of an Era – A Guide for Rational Capital Allocation in the New Private Biopharmaceutical Market

Up. That is the only direction the private biopharmaceutical market has known in the 5 years from 2017 to 2021 with total investments in private biopharmaceutical companies more than doubling from $12.3B in 2017 to $28.5B in 2021.

06.24.22

Headwinds And Opportunities in Biopharma

Although the biopharmaceutical sector is facing major headwinds due to a tough regulatory and political environment, COVID, inflation, rising interest rates, geopolitical stability, overcapitalized innovation, poor managerial execution, and more